Patients treated with ipilimumab plus gp100 in MDX010-20 also reported late-onset AEs including grade 1 vitiligo (n = 3, 5.6 %), grade 2 hypogonadism and reduced serum testosterone (n = 1, 1.9 %), and grade 1 diarrhea, grade 2 proctitis, and grade 3 colitis (n = 1, 1.9 %) [17]. This evidence concerns the gene PMEL and vitiligo.